Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110755 | 0.90 | HTR6 (0.39) | HTR6CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL27933961 | 0.88 | HTR6 (0.36) | HTR6CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL19221842 | 0.84 | HTR6 (0.38) | HTR6ALDH1A1MAPT | |
| SCHEMBL458128 | 0.84 | HTR6 (0.39) | HTR6CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL660444 | 0.82 | PIK3CD (0.41) | HTR6ALDH1A1MAPT | |
| SCHEMBL15049938 | 0.82 | PIK3CD (0.41) | HTR6ALDH1A1MAPT | |
| SCHEMBL657902 | 0.82 | PIK3CD (0.41) | HTR6ALDH1A1MAPT | |
| SCHEMBL13075179 | 0.80 | CYP1A2 (0.34) | HTR6CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL109862 | 0.80 | ALDH1A1 (0.42) | NPSR1ALDH1A1MAPT | |
| SCHEMBL111538 | 0.80 | KMT2A (0.39) | HTR6CYP2C19CYP3A4CYP2D6NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | HTR6 4089/4885CYP2C19 754/4885CYP3A4 1034/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | HTR6 4089/4885CYP2C19 754/4885CYP3A4 1034/4885 |
| US-20190328744-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | HTR6 4445/4885CYP2C19 1942/4885CYP3A4 1813/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | HTR6 3865/4885CYP2C19 4031/4885CYP3A4 3699/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885CYP3A4 1686/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885CYP3A4 1686/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | HTR6 4445/4885CYP2C19 1942/4885CYP3A4 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.